|Day Low/High||44.16 / 47.71|
|52 Wk Low/High||18.93 / 59.25|
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
The company has spent a lot of time and money trying to meet the supply needs of the recreational cannabis market.
A pair of earnings report this week will shed light on the future direction of two fast-growing companies in very different fields.
The action in pot stocks continues to be poor. I have a very small position in and even though the shares might be attractive over the long run, I won't be adding until I see some better price action. I have been cautious on the group for some time ...
Oh, by the way, Constellation, for those who've forgotten, holds a 38% stake in Canopy Growth.
There is certainly too much to ignore about STZ for the majority of analysts.
What I do know is that TSLA now faces a tumultuous uphill battle in order to meet its full year guidance.
What to look for when Dave & Buster's and Constellation Brands report results.
The fact that everyone wants to know everyone's thoughts about Canopy Growth should tell you everything you want to know about CGC's current valuation and ownership. In fact, the Canadian LPs (Licensed Producers) are a tough game right now. These ar...
The pot sector has been weak recently. I own a very small long position in which is -$1 to under $44/share (which was added to my Best Ideas List on January 2, 2019 at $27.75) As I mentioned I wasn't willing to pay up for recently and, in general, ...
A huge week is coming up for these well-known stocks.
Investors can gain exposure to the high-flying cannabis industry without taking on undue risks.
Yesterday I reestablished a long position in Canopy Growth - which has been on my Best Ideas List since early January, 2019. The shares are responding well to this news.
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Apparently, this game is all about growth right now. It certainly is not about margins.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
I am back long Canopy Growth (very) small (I bought the opening). Moved up my buy entry price in light of a market that seems to be more accepting of speculative stocks.
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Assessing Aurora and its peers, strictly on the numbers.
In this day and age, companies must be 'disruptors' or get left in the dust.
Peltz's addition should pacify a persistent critique of the company.
Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.
Here are some of my individual buy levels of stocks that I want to add to or reestablish on weakness: * $157.50 * $1625 * $1150 * $42 * $55 * $46 * $46.50 * $182.50 * $31 * $40 * $23 * $65 * $16.75 * $35 * $27.75 * $60 * $95 * $48 * $87.50 Note: Lon...
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
Aurora's prominent partner could be cannabis' key to breaking into consumer segments.